The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

According to Makary and Prasad, the US’s adoption of a “one-size-fits-all” guidance for COVID-19 vaccination departs from ...

Nucleoside reverse transcriptase inhibitors appear to be neuroprotective, thus lowering the incidence of Alzheimer dementia.

Moderna has withdrawn the Biologics License Application (BLA) for mRNA-1083, a combination vaccine against seasonal influenza and SARS-CoV-2, after ...

The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was ...

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

Jivi is not indicated for use in patients less than 7 years old due to a greater risk for hypersensitivity reactions and/or loss of efficacy. The Food and Drug Administration (FDA) has expanded ...

Findings showed a significantly greater proportion of patients treated with AD109 had an improvement (reduction) in AHI score compared with those who received placebo. Topline data were announced ...

No gynecological malignancies were seen, while expected incidence was 0.26 or greater for all cancer types. HealthDay News — Short-term testosterone use among transmasculine and gender diverse ...